help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-1920
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/6/3696    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charmandari, E.
Right arrow Articles by Chrousos, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charmandari, E.
Right arrow Articles by Chrousos, G. P.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*OMIM
*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DEXAMETHASONE
Medline Plus Health Information
*Steroids
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Neuroendocrinology and Pituitary
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 6 3696-3705
Copyright © 2005 by The Endocrine Society

A Novel Point Mutation in the Ligand-Binding Domain (LBD) of the Human Glucocorticoid Receptor (hGR) Causing Generalized Glucocorticoid Resistance: The Importance of the C Terminus of hGR LBD in Conferring Transactivational Activity

Evangelia Charmandari, Annaswamy Raji, Tomoshige Kino, Takamasa Ichijo, Anatoly Tiulpakov, Keith Zachman and George P. Chrousos

Pediatric and Reproductive Endocrinology Branch (E.C., T.K., T.I., A.T., K.Z., G.P.C.), National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892; and Department of Endocrinology, Brigham and Women’s Hospital, Harvard Medical School (A.R.), Boston, Massachusetts 02115

Address all correspondence and requests for reprints to: Dr. Evangelia Charmandari, Department of Pediatric Endocrinology, Great Ormond Street Hospital for Children, 9th Floor, Southwood Building, Great Ormond Street, London, United Kingdom WC1N 3JH. E-mail: charmane{at}mail.nih.gov.

Glucocorticoid resistance is a rare, familial or sporadic condition characterized by partial end-organ insensitivity to glucocorticoids. The clinical spectrum of the condition is broad, ranging from completely asymptomatic to severe hyperandrogenism and/or mineralocorticoid excess. The molecular basis of glucocorticoid resistance has been ascribed to mutations in the human glucocorticoid receptor-{alpha} (hGR{alpha}) gene, which impair one or more of the molecular mechanisms of GR action, thus altering tissue sensitivity to glucocorticoids. We identified a new case of generalized glucocorticoid resistance in a young woman who presented with a long-standing history of fatigue, anxiety, hyperandrogenism, and hypertension. The disease was caused by a novel, heterozygous mutation (T->C) at nucleotide position 2318 (exon 9) of the hGR{alpha} gene, which resulted in substitution of leucine by proline at amino acid position 773 in the ligand-binding domain of the receptor. We systematically investigated the molecular mechanisms through which the natural hGR{alpha}L773P mutant impaired glucocorticoid signal transduction. Compared with the wild-type hGR{alpha}, hGR{alpha}L773P demonstrated a 2-fold reduction in the ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter, exerted a dominant negative effect on the wild-type receptor, had a 2.6-fold reduction in the affinity for ligand, showed delayed nuclear translocation (30 vs. 12 min), and, although it preserved its ability to bind to DNA, displayed an abnormal interaction with the GR-interacting protein 1 coactivator in vitro. We conclude that the carboxyl terminus of the ligand-binding domain of hGR{alpha} is extremely important in conferring transactivational activity by altering multiple functions of this composite transcription factor.




This article has been cited by other articles:


Home page
IOVSHome page
A. Nehme and J. Edelman
Dexamethasone Inhibits High Glucose-, TNF-{alpha}-, and IL-1{beta}-Induced Secretion of Inflammatory and Angiogenic Mediators from Retinal Microvascular Pericytes
Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 2030 - 2038.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Charmandari, T. Kino, T. Ichijo, and G. P. Chrousos
Generalized Glucocorticoid Resistance: Clinical Aspects, Molecular Mechanisms, and Implications of a Rare Genetic Disorder
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1563 - 1572.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
H. Raef, E. Y Baitei, M. Zou, and Y. Shi
Genotype-phenotype correlation in a family with primary cortisol resistance: possible modulating effect of the ER22/23EK polymorphism.
Eur. J. Endocrinol., April 1, 2008; 158(4): 577 - 582.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Charmandari, T. Kino, T. Ichijo, W. Jubiz, L. Mejia, K. Zachman, and G. P. Chrousos
A Novel Point Mutation in Helix 11 of the Ligand-Binding Domain of the Human Glucocorticoid Receptor Gene Causing Generalized Glucocorticoid Resistance
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3986 - 3990.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. Sanchez-Vega, N. Krett, S. T. Rosen, and V. Gandhi
Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells
Mol. Cancer Ther., December 1, 2006; 5(12): 3062 - 3070.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. G. Riepe, J. Finkeldei, L. de Sanctis, S. Einaudi, A. Testa, B. Karges, M. Peter, M. Viemann, J. Grotzinger, W. G. Sippell, et al.
Elucidating the Underlying Molecular Pathogenesis of NR3C2 Mutants Causing Autosomal Dominant Pseudohypoaldosteronism Type 1
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4552 - 4561.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Charmandari, T. Kino, T. Ichijo, K. Zachman, A. Alatsatianos, and G. P. Chrousos
Functional Characterization of the Natural Human Glucocorticoid Receptor (hGR) Mutants hGR{alpha}R477H and hGR{alpha}G679S Associated with Generalized Glucocorticoid Resistance
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1535 - 1543.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Ichijo, A. Voutetakis, A. P. Cotrim, N. Bhattachryya, M. Fujii, G. P. Chrousos, and T. Kino
The Smad6-Histone Deacetylase 3 Complex Silences the Transcriptional Activity of the Glucocorticoid Receptor: POTENTIAL CLINICAL IMPLICATIONS
J. Biol. Chem., December 23, 2005; 280(51): 42067 - 42077.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society